Clinical Trial Detail

NCT ID NCT03929029
Title Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

melanoma

Therapies

Ipilimumab + NeoVax + Nivolumab

Age Groups: adult senior

No variant requirements are available.